Jolien Suurmond

Jolien Suurmond

Auto-generated profile, based on publicly available information

Jolien Suurmond

Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJolien Suurmond
Jolien Suurmond
BDBetty Diamond
Betty Diamond
In this Review we focus on the initiation of autoantibody production and autoantibody pathogenicity, with a special emphasis on the targeted antigens. Release of intracellular antigens due to excessive cell death or to ineffective clearance of apoptotic debris, modification of self-antigens during inflammatory responses, and molecular mimicry contribute to the initiation of autoantibody production. We hypothesize that those autoreactive B cells that survive and produce pathogenic autoantibodies have specificity for self-antigens that are TLR ligands. Such B cells experience both B cell receptor (BCR) activation and TLR engagement, leading to an escape from tolerance. Moreover, the autoantibodies they produce form immune complexes that can activate myeloid cells and thereby establish the proinflammatory milieu that further negates tolerance mechanisms of both B and T cells.

3 November 2016 in Blood
Verified
Journal Article
Open access
PDF file
MSMyoungsun Son
Myoungsun Son
APAmit Porat
Amit Porat
MHMingzhu He
Mingzhu He
JSJolien Suurmond
Jolien Suurmond
FSFrances Santiago-Schwarz
Frances Santiago-Schwarz
BDBetty Diamond
Betty Diamond
Key Points: C1q can form a multimolecular signaling complex with HMGB1, RAGE, and LAIR-1 in lipid rafts. C1q and HMGB1 together promote monocytes to differentiate to an anti-inflammatory phenotype.

5 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SMSusan Malkiel
Susan Malkiel
ABAshley N. Barlev
Ashley N. Barlev
YAYemil Atisha-Fregoso
Yemil Atisha-Fregoso
JSJolien Suurmond
Jolien Suurmond
BDBetty Diamond
Betty Diamond
Plasma cells (PCs) are responsible for the production of protective antibodies against infectious agents but they also produce pathogenic antibodies in autoimmune diseases, such as systemic lupus erythematosus (SLE). Traditionally, high affinity IgG autoantibodies are thought to arise through germinal center (GC) responses. However, class switching and somatic hypermutation can occur in extrafollicular (EF) locations, and this pathway has also been implicated in SLE. The pathway from which PCs originate may determine several characteristics, such as PC lifespan and sensitivity to therapeutics. Although both GC and EF responses have been implicated in SLE, we hypothesize that one of these pathways dominates in each individual patient and genetic risk factors may drive this predominance. While it will be important to distinguish polymorphisms that contribute to a GC-driven or EF B cell response to develop targeted treatments, the challenge will be not only to identify the differentiation pathway but the molecular mechanisms involved. In B cells, this task is complicated by the cross-talk between the B cell receptor, toll-like receptors (TLR), and cytokine signaling molecules, which contribute to both GC and EF responses. While risk variants that affect the function of dendritic cells and T follicular helper cells are likely to primarily influence GC responses, it will be important to discover whether some risk variants in the interferon and TLR pathways preferentially influence EF responses. Identifying the pathways of autoreactive PC differentiation in SLE may help us to understand patient heterogeneity and thereby guide precision therapy.

15 January 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
EBEmilie P. Buddingh
Emilie P. Buddingh
MSMarco W. Schilham
Marco W. Schilham
SRS. Eriaty N. Ruslan
S. Eriaty N. Ruslan
DBDagmar Berghuis
Dagmar Berghuis
Karoly SzuhaiKaroly Szuhai
Karoly Szuhai
ALArjan C. Lankester
Arjan C. Lankester
High-grade osteosarcoma occurs predominantly in adolescents and young adults and has an overall survival rate of about 60%, despite chemotherapy and surgery. Therefore, novel treatment modalities are needed to prevent or treat recurrent disease. Natural killer (NK) cells are lymphocytes with cytotoxic activity toward virus-infected or malignant cells. We explored the feasibility of autologous and allogeneic NK cell–mediated therapies for chemotherapy-resistant and chemotherapy-sensitive high-grade osteosarcoma. The expression by osteosarcoma cells of ligands for activating NK cell receptors was studied in vitro and in vivo, and their contribution to NK cell–mediated cytolysis was studied by specific antibody blockade. Chromium release cytotoxicity assays revealed chemotherapy-sensitive and chemotherapy-resistant osteosarcoma cell lines and osteosarcoma primary cultures to be sensitive to NK cell–mediated cytolysis. Cytolytic activity was strongly enhanced by IL-15 activation and was dependent on DNAM-1 and NKG2D pathways. Autologous and allogeneic activated NK cells lysed osteosarcoma primary cultures equally well. Osteosarcoma patient–derived NK cells were functionally and phenotypically unimpaired. In conclusion, osteosarcoma cells, including chemoresistant variants, are highly susceptible to lysis by IL-15-induced NK cells from both allogeneic and autologous origin. Our data support the exploitation of NK cells or NK cell–activating agents in patients with high-grade osteosarcoma.

9 October 2013 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JSJolien Suurmond
Jolien Suurmond
JSJeroen N. Stoop
Jeroen N. Stoop
FRFelice Rivellese
Felice Rivellese
ABAleida M. Bakker
Aleida M. Bakker
THTom W. J. Huizinga
Tom W. J. Huizinga
RTRené E. M. Toes
René E. M. Toes
Basophils are mostly known for their involvement in allergic reactions. Recent studies in mice indicate a role for basophils in the induction of adaptive immunity, especially T helper 2 (Th2) responses. Therefore, it would be highly important to understand how basophils respond to pathogen‐associated molecules, such as ligands for toll‐like receptors (TLRs), and if the basophils could promote Th2 responses via these stimuli. To this end, the activation of basophils via TLRs in combination with activation via IgE was studied, as well as its effect on T helper cell skewing. Using quantitative PCR, we demonstrated the presence of mRNA for TLRs 1–8 in human basophils. Basophils responded to TLR triggering with differential cytokine production, but not with degranulation. Simultaneous triggering of TLRs and IgE led to synergy in production of IL‐4, IL‐8, IL‐13, and RANTES. Furthermore, the synergistic effects on basophils mediated by IgE and TLR‐4 triggering allowed robust Th2 skewing upon activation of naïve human CD4+ T cells.Our data show that human basophils respond to TLR ligands in synergy with IgE‐mediated activation and that the cytokines produced can promote Th2 differentiation. These results indicate a role for basophils in the regulation of T‐cell responses in humans.

20 September 2011 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JSJolien Suurmond
Jolien Suurmond
ADAnnemarie L Dorjée
Annemarie L Dorjée
MBMariëtte Boon
Mariëtte Boon
FKFrank Knol
Frank Knol
THTom Wj Huizinga
Tom Wj Huizinga
ASAnnemie Jm Schuerwegh
Annemie Jm Schuerwegh
Introduction: Mast cells have been implicated to play a functional role in arthritis, especially in autoantibody-positive disease. Among the cytokines involved in rheumatoid arthritis (RA), IL-17 is an important inflammatory mediator. Recent data suggest that the synovial mast cell is a main producer of IL-17, although T cells have also been implicated as prominent IL-17 producers as well. We aimed to identify IL-17 expression by mast cells and T cells in synovium of arthritis patients. Methods: Synovial samples of anticitrullinated protein antibody-positive (ACPA+) and ACPA-negative (ACPA-) RA and osteoarthritis (OA) patients were stained for IL-17 in combination with CD117 (mast cells), CD3 (T cells) and CD68 (macrophages). Concentrations of IL-17 in synovial fluid were determined by ELISA. Results: The number of IL-17+ cells in synovium was comparable in all groups. Although the vast majority of IL-17+ cells are mast cells, no difference in the percentage of IL-17+ mast cells was observed. Nonetheless, levels of IL-17 in synovial fluid were increased in ACPA+ RA patients compared to ACPA- RA and OA patients. Conclusions: The synovial mast cell is the main IL-17+ cell in all three arthritis groups analyzed. These data are relevant for studies aimed at blocking IL-17 in the treatment of arthritis.